Search This Blog

Tuesday, May 6, 2025

Addus (ADUS) Q1 Revenue Rises, Boosted by Gentiva Acquisition

 Addus (ADUS, Financial) reported first-quarter revenue of $337.7 million, slightly below market expectations of $339.92 million. Despite missing revenue forecasts, the company demonstrated a strong beginning to 2025, with a 20.3% increase in revenue compared to the previous year. Additionally, adjusted EBITDA saw a significant rise of 25.1% from the same period last year.

These positive results highlight robust organic growth and include the impact of the personal care segment of Gentiva, which was fully integrated during the quarter after its acquisition on December 2, 2024. Addus continues to experience strong demand for its home-based care services, contributing to this successful quarter.

Wall Street Analysts Forecast

1919491097005027328.png

Based on the one-year price targets offered by 9 analysts, the average target price for Addus HomeCare Corp (ADUSFinancial) is $141.56 with a high estimate of $160.00 and a low estimate of $120.00. The average target implies an upside of 35.63% from the current price of $104.37. More detailed estimate data can be found on the Addus HomeCare Corp (ADUS) Forecast page.

Based on the consensus recommendation from 11 brokerage firms, Addus HomeCare Corp's (ADUSFinancial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. 

https://www.gurufocus.com/news/2829973/addus-adus-q1-revenue-rises-boosted-by-gentiva-acquisition-adus-stock-news

Bessent says US on debt-limit ‘warning track,’ but no timing yet

 Treasury Secretary Scott Bessent repeated his warning that his department is on the “warning track” toward exhausting its capacity to stay within the federal debt limit, while refraining from offering a specific timeframe on Tuesday.

“We will share with Congress when we believe we are” approaching the so-called X-date, when Treasury will be unable to pay all of the government’s bills on time, Bessent said in answering questions at the House Appropriations Committee. He said the Treasury is still tallying tax revenue from the latest filing season.

The debt ceiling kicked back in at the start of January, and the Treasury has been using special accounting maneuvers to avoid breaching the limit while maintaining payments on federal obligations. Wall Street analysts have estimated the Treasury has until an August-to-October period before it will need Congress to increase or set aside the debt limit.

“We are on the warning track,” Bessent said. He also reiterated that the US government will never default, and pledged that the Treasury will not use “gimmicks” to get around the debt limit.

https://finance.yahoo.com/news/bessent-says-us-debt-limit-144038350.html

Kennedy aide and vaccine critic questions recent panel recommendations

 An aide to U.S. Health Secretary Robert F. Kennedy Jr. is seeking more information about three vaccines recommended by a panel of outside experts last month, according to documents reviewed by Reuters and two sources familiar with the situation.

The advisory panel to the Centers for Disease Control and Prevention had made recommendations regarding the use of separate shots approved to help protect against RSV, meningitis and chikungunya. The CDC is not required to adopt their recommendations, but when it does, they become guidelines for medical practitioners to follow.

Dr. William “Reyn” Archer III joined the Health and Human Services Department, which oversees CDC, as a counselor in the secretary's office after Kennedy took over in February, HHS records show. A critic of vaccines on social media for the past several years, Archer served as Texas state health commissioner in the late 1990s.

Archer’s hiring and activity at HHS have not previously been reported. His role reviewing the Advisory Committee on Immunization Practices’ recommendations is the latest indication of how Kennedy, who has spent decades raising doubts about the safety and efficacy of vaccines, is reshaping U.S. policy.

HHS spokesman Andrew Nixon said the agency "will ensure that all recommendations adhere to the Gold Standard of Science."

As part of his HHS role, Archer has in recent days posed questions to the CDC about the advisory committee recommendations, according to the documents and the two sources.

One recommendation would expand eligibility for RSV vaccines made by Pfizer and GSK to high-risk adults aged 50-59 from a current threshold age of at least 60 years.

In response, Archer asked for more justification of the expansion given what he described as a “possible decline in efficacy with a second dose,” according to the documents and two sources.

It is unclear what decline in efficacy data Archer is referring to. At the ACIP meeting, a GSK representative presented clinical trial results the company described as showing “robust” immune responses following re-vaccination at 24 and 36 months.

A GSK spokesperson said the data showed waning efficacy of a single dose over time, but not enough to justify revaccination yet. A Pfizer spokesperson did not immediately respond to requests for comment.

ACIP also voted to recommend expanded use of GSK's vaccine for meningitis, and Archer questioned how providers administer it.

In addition, ACIP recommended the use of a new chikungunya vaccine from Bavarian Nordic, which Archer has not disputed. However, Kennedy's aide asked for more information about a recommendation to expand the use of a vaccine for the mosquito-borne virus made by Valneva, the documents show.

Archer also asked to know what adjuvants and platforms are being used for all the vaccines discussed at the ACIP meeting, and their length of immunity.

FROM TEXAS TO WASHINGTON

Kennedy is currently reviewing the latest ACIP recommendations in the absence of a CDC director, and it is unclear whether the HHS secretary will ultimately sign off on them.

The decision will impact public health and major drug companies. Pfizer and GSK last month touted ACIP’s vote to lower the age at which adults can be eligible for their respective RSV vaccines, decisions that affect whether insurers will likely pay for them. The FDA previously approved the age expansion.

Kennedy says he is not opposed to vaccination, but described them as a personal choice in the midst of a large U.S. measles outbreak mostly among the unvaccinated. Kennedy argues that the nation's health bureaucracy should focus on chronic illness.

Archer is a trained obstetrician who served in the early 1990s as a deputy assistant secretary of HHS under the administration of George H.W. Bush. At HHS, he helped implement a so-called gag rule restricting medical providers at federally-funded clinics from advising patients on abortion, according to court documents and media reports.

He was appointed by then-Texas Governor George W. Bush to serve as commissioner of the state's Department of Health. He resigned in 2000 after a Black administrator in the department secretly recorded him making comments about her race, according to an Associated Press report at the time.

Archer later served as chief of staff for Congressman Jeff Fortenberry of Nebraska from 2016 to 2022, according to his LinkedIn profile.

Fortenberry, who opposed COVID-19 vaccine mandates during his tenure, was subsequently charged with lying to federal authorities about a campaign donation. The Justice Department dropped those charges after President Donald Trump took office in January.

On his personal Facebook page, Archer posted repeatedly from 2020 to 2022 about the "limitations" of the COVID vaccine, Reuters found. In a deleted post on X, accessed with the Internet Archive, Archer said as Texas health commissioner he felt pressure to support vaccine mandates without "scientific counterfactual.”

"My own son developed autism in early years then took his life at 16," he said in the post, which linked to a Trump campaign ad critical of the measles vaccine.

https://www.aol.com/news/exclusive-kennedy-aide-vaccine-critic-100412716.html

CorMedix First Ever Profitable Quarter with $39.1M Revenue, Raises Guidance

CorMedix Inc. (CRMD) reported strong Q1 2025 financial results with net revenue of $39.1 million and net income of $20.6 million ($0.32 per share), compared to a net loss in Q1 2024. The company achieved adjusted EBITDA of $23.6 million and positive cash flow from operations of $19.7 million. DefenCath sales drove performance, particularly in outpatient dialysis. The inpatient sales team is now fully operational, with institutional shipments doubling over three months. CorMedix commenced a Phase 3 study for reducing CLABSIs in TPN patients. The company expects to hit the high end of its H1 2025 sales guidance ($62-70 million) and reported cash and short-term investments of $77.5 million, sufficient for at least 12 months of operations.

Actions to Reduce Regulatory Barriers to Domestic Pharmaceutical Manufacturing

PROMOTING AMERICAN-MADE PRESCRIPTION DRUGS: Today, President Donald J. Trump signed an Executive Order to facilitate the restoration of a robust domestic manufacturing base for prescription drugs, including key ingredients and materials necessary to manufacture prescription drugs.

  • The Order directs the U.S. Food and Drug Administration (FDA) to reduce the amount of time it takes to approve domestic pharmaceutical manufacturing plants by eliminating duplicative and unnecessary requirements, streamlining reviews, and working with domestic manufacturers to provide early support before facilities come online.
    • The Order directs the FDA to increase fees for and inspections of foreign manufacturing plants.
    • President Trump is directing the FDA to improve enforcement of active pharmaceutical ingredient source reporting by foreign drug producers and consider publicly displaying a list of facilities that do not comply.
  • The Order directs the Environmental Protection Agency (EPA) to accelerate the construction of facilities designed to manufacture prescription drugs, active pharmaceutical ingredients, and other necessary raw materials.
  • The Order ensures that federal agencies issuing permits for a domestic pharmaceutical manufacturing facility designate a single point-of-contact to coordinate permit applications with interagency support from the White House Office of Management and Budget (OMB) to ensure an efficient and coordinated process.

UNLEASHING PROSPERITY AND PROTECTING NATIONAL SECURITY THROUGH PERMITTING REFORM: President Trump is clearing bureaucratic obstacles to critical domestic pharmaceutical manufacturing in order to usher in America’s new Golden Age by ensuring access to the medicines Americans need.

  • Critical barriers and gaps still exist in establishing a domestic, resilient, and affordable pharmaceutical supply chain for American patients.
    • New construction must navigate myriad Federal, State, and local requirements ranging from building standards and zoning restrictions to environmental protocols that together diminish the certainty needed to generate investment for large manufacturing projects.
  • Estimates suggest that building new manufacturing capacity for pharmaceuticals and critical inputs may take as long as five to ten years, which is unacceptable from a national-security standpoint.
  • This Order will speed up timelines for building domestic pharmaceutical manufacturing site by reducing regulatory barriers to construction.

DELIVERING ON PROMISES TO PUT AMERICA FIRST: President Trump is delivering on his promise to once again put America first by ensuring the FDA prioritizes American manufacturing facilities over foreign facilities.

  • President Trump: “We don’t want to be buying our pharmaceuticals from other countries because if we’re in a war, we’re in a problem, we want to be able to make our own.”
  • President Trump: “As we invest in the future, we will permanently bring our medical supply chains back home. We will produce our medical supplies, pharmaceuticals, and treatments right here in the United States.”
  • This Order builds on actions from President Trump’s first term to re-shore production of essential medicines and cut down our reliance on foreign producers. 

FOXO Healthcare Subsidiary Hits Major Milestone: 5,000 Care Days Served, Eyes Rapid Expansion



FOXO Technologies (NYSE American: FOXO) announced significant operational achievements for its behavioral health subsidiary, Myrtle Recovery Centers. Since launching in Oneida, Tennessee in August 2023, the facility has:

- Treated over 400 patients
- Provided 5,000+ care days
- Projects 10,000 patient care days by end of 2025

Myrtle's CEO Robert Merritt highlighted the facility's strong reputation in East Tennessee for substance use disorder treatment. FOXO's CEO Seamus Lagan expressed satisfaction with the investment and indicated plans for expansion to additional locations to increase revenue contribution.

Major Israeli Attack Destroys Yemen's Sanaa International Airport

 Israel's air force has continued a second day of large-scale attacks on Yemen, targeting the leadership and infrastructure of the Ansarallah movement, or Houthis, after the Sunday Houthi ballistic missile strike on Israel's Ben Gurion international airport in Tel Aviv.

Huge plumes of black smoke have been observed rising above the Houthi-controlled airport area in the capital of Sana'a. Prior Israeli strikes, with US backing, focused on the vital port of Hodeidah.

Within a couple hours before the Tuesday Israeli strikes on Sana'a commencing, the IDF military issued an evacuation warning for Yemen's Sana'a International Airport, stated that being near it "exposes you to danger."

This warning was given because Israel is fully aware that this is a civilian aviation hub. However, Israeli officials have accused the Houthis of using it as a military base and staging ground.

"We call upon you to evacuate the airport area -- Sana'a International Airport -- immediately and warn everyone in your vicinity of the need to evacuate this area immediately," the IDF's Arabic spokesman warned earlier Tuesday. "Failure to evacuate and move away from the place exposes you to danger."

Several power stations in the area of the Yemeni capital have also been hit, initial reports say. "Among the targets were the Dhahban and Haiz power stations, a cement plant in Amran, and civilian aircraft and terminals at the airport," according to regional media.

The IDF has previously alleged that the Houthis use cement from the targeted factory to erect tunnels and military infrastructure, amid international criticism accusing Israel of destroying vital civilian infrastructure.

The Israeli army has issued a full statement which reads as follows:

For the second time in less than 24 hours, the Israeli Air Force struck Houthi terror targets in Yemen. The IAF recently destroyed infrastructure at Sana’a’s main airport, rendering it completely inoperable, in response to a Houthi missile launch at Ben Gurion Airport. Like the Hodeidah port hit earlier, the airport was used by the Houthis to transfer weapons and fighters, and regularly served the group’s terror activities.

The IDF also struck key power stations around Sana’a, which the Houthis exploited as a major energy supply source for their operations—another example of using civilian infrastructure for terror. Additionally, the Al-Amran cement factory north of Sana’a, crucial for tunnel and military infrastructure construction, was hit—impacting the Houthi economy and military buildup.

But if the Houthis have demonstrated anything, it is their resolve and refusal to back down even after months of American-led major attacks. Likely they will ramp up efforts to target Israeli and American assets.

Massive destruction and smoke clouds over Yemen's main international airport and flight hub...

Given this new targeting of Yemen's international airport, this could invite Houthi efforts to double down on targeting Ben Gurion in Tel Aviv. Is an airport strike tit-for-tat on the horizon? Certainly this is bad news for civilian aviation and safety in the whole region.

The United States has been supporting Israel's 'retaliatory' action, and Houthi leadership has confirmed that the Monday strikes on Hodeidah were the result of "US-Israeli aggression".

Sanaa Airport has already suffered damage from coalition attacks, including this from December 27, 2024. via Reuters

Currently the US has two aircraft carriers and accompanying warships in the Red Sea region, and they might be further targeted with drone and rocket attacks.

The US Navy/CENTCOM has already for months been fending off sporadic fire from Yemen, but things seem to be escalating at this point.

The Trump administration has recently been accused of hiding US casualties in this now long-running Red Sea naval battle, which is turning into yet another Washington quagmire in the Middle East.

https://www.zerohedge.com/geopolitical/major-israeli-attack-destroys-yemens-sanaa-international-airport